This invention relates to compounds and methods for the treatment of a co ndition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula (I) or pharmac eutically acceptable salts thereof, wherein: A, B, R1, R2 and R3 are each as described herein. These compounds are useful in the treatment of a conditio n mediated by CB2 receptor binding activity such as, but not limited to, inf lammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic lo w back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acu te pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropat hy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoar thritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, s ciatica, inflammation, neurodegenerative disease, spasticity, epilepsy, Tour ette's syndrome, Parkinson's disease, neuroprotection, anxiety, cough, bronc ho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, cachexia, nausea, emesis, chemothe rapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerati ve colitis, asthma, dermatitis, seasonal allergic rhinitis, gastroesophageal reflux disease (GERD), constipation, diarrhea, functional gastrointestinal disorder, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, pso riasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glom erulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasod ialation, hypertension, vasculitis, myocardial infarction, cerebral ischemia , reversible airway obstruction, adult respiratory disease syndrome, chronic obstructive pulmonary disease (COPD), cryptogenic fibrosing alveolitis and bronchitis.
BENZIMIDAZOLONE DERIVATIVES